Comparing the efficacy of N‐acetylcysteine plus carvedilol versus carvedilol in the prevention of atrial fibrillation following coronary artery bypass graft surgery.

Background: Atrial fibrillation (AF) is the most common arrhythmia following open‐heart surgery. Agents with antioxidant properties may reduce postoperative complications like postoperative AF (POAF) in patients undergoing open‐heart surgery. This study was conducted to assess the effect of N‐acetylcysteine (NAC) in prevention of AF following coronary artery bypass graft (CABG) surgery. Methods: Three hundred patients who underwent CABG surgery were entered in the study. Patients with contraindications for beta‐blockers and patients were simultaneously replacing or repairing the valve with open‐heart surgery were excluded. The patients were randomly divided into two groups (n = 150) and they were received NAC plus carvedilol or carvedilol. The patients were monitored for 5 days after surgery and the incidence of AF during hospitalization was recorded. Results: AF was detected in 14 patients in the NAC with Carvedilol group (9.33%) and 23 patients in Carvedilol group (15.33%). There was no significant difference in the incidence of POAF between the two groups (p value = 0.112). The result of multivariable regression model represented that although the incidence of POAF was lower in NAC plus carvedilol group, it wasn't statistically significant (p value = 0.10). Conclusions: NAC was not associated with a decreased incidence of AF following CABG surgery. [ABSTRACT FROM AUTHOR]